Similarly, a great proportion of HER2+-BC patients fail to respond or rapidly develop resistance to anti-HER2 therapies due to compensatory tumor-promoting pathways, thereby leading to a frequent cancer relapse and metastasis [4]. Here, ERBB2 is linked to breast cancer.